MACROGENICS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount
MACROGENICS, INC. (MGNX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount of $10.85 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsOther · last filed 2023-03-15
- MACROGENICS, INC. effective income tax rate reconciliation, tax credit, other, amount for fiscal 2022 was $10.85M, a 648.52% increase from fiscal 2021.
- MACROGENICS, INC. effective income tax rate reconciliation, tax credit, other, amount for fiscal 2021 was $1.45M, a 174.43% increase from fiscal 2020.
- MACROGENICS, INC. effective income tax rate reconciliation, tax credit, other, amount for fiscal 2020 was $528.00K, a 75.42% increase from fiscal 2019.
- MACROGENICS, INC. effective income tax rate reconciliation, tax credit, other, amount for fiscal 2019 was $301.00K, a 65.48% decline from fiscal 2018.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount 12 month as first filed |
|---|---|---|
| 2022-12-31 | $10.85M 10-K · filed 2023-03-15 | |
| 2021-12-31 | $1.45M 10-K · filed 2023-03-15 | |
| 2020-12-31 | $528.00K 10-K · filed 2023-03-15 | |
| 2019-12-31 | $301.00K 10-K · filed 2022-02-24 | |
| 2018-12-31 | $872.00K 10-K · filed 2021-02-25 | |
| 2017-12-31 | $1.85M 10-K · filed 2020-02-25 | |
| 2016-12-31 | $571.00K 10-K · filed 2019-02-26 | |
| 2015-12-31 | $106.00K 10-K · filed 2018-02-27 | |
| 2014-12-31 | $139.00K 10-K · filed 2017-02-28 | |
| 2013-12-31 | $843.00K 10-K · filed 2016-02-29 | $843.46K 10-K · filed 2014-03-20 |
| 2012-12-31 | $4.90M 10-K · filed 2015-03-03 | $4.90M 10-K · filed 2014-03-20 |
| 2011-12-31 | $7.06M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |